Privately held ARYx Therapeutics Inc. signed its first major partnership since its founding in 1998, granting to Procter & Gamble Pharmaceuticals Inc. worldwide development and commercialization rights to ATI-7505 in gastrointestinal disorders. (BioWorld Today)

Valentis Considers Sale After PAD Drug's Miss In Phase IIb

July 12, 2006

By Karen Carey

Investors in Valentis Inc. took a devastating blow Tuesday, when the company reported lead drug VLTS 934 failed to show a statistically significant difference from placebo in a Phase IIb peripheral arterial disease study. (BioWorld Today)

Novozymes Getting Protein Production, More From Delta

July 12, 2006

By Karen Carey

Athenagen Gains New AD Platform Via Zapaq Merger

July 11, 2006

By Karen Carey

Adding a new Alzheimer's disease platform to its portfolio, Athenagen Inc. agreed to merge with Zapaq Inc., a 5-year-old company focused on beta-secretase inhibitors. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...